Sign inJoin waitlistJoin the waitlist

FI

Fabio Iwamoto

Co-Director of the Stanford Brain Tumor Center · Stanford Health Care

Credentials: · · · ·

History

Stanford Brain Tumor Center · Stanford Health Care
Present
Stanford Health Care
Present
Stanford Health Care
Present

New York Presbyterian Hospital
2025–2026
Memorial Sloan Kettering Cancer Center
2006–2008
Neurology
New York Presbyterian Hospital
2002–2006
Doctor of Medicine
1995–1999

Research

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
The Lancet Oncology · 2017 · 932 citations
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Nature Medicine · 2019 · 762 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Journal of Translational Medicine · 2018 · 425 citations

LA
Lauren Abrey
26 papers
Andrew Lassman
22 papers
Jeffrey Bruce
18 papers
LD
Lisa DeAngelis
18 papers
Tony Wang
16 papers
Howard Fine
15 papers
Michael Sisti
15 papers
Guy McKhann
13 papers
TK
Teri Kreisl
13 papers
Adam Worthalter
12 papers · 3 as a resident
Simon Cheng
12 papers
Lakshmi Nayak
11 papers · 4 as a fellow

Grants

Genetic Correlation with Efficacy and Toxicity of Brain Tumor Therapies
National Cancer Institute · ZIA
Contact PI · $274.5K · Division of Basic Sciences - Nci
Aging and Primary Central Nervous System Tumors
National Cancer Institute · ZIA
Contact PI · $274.5K · Division of Basic Sciences - Nci

Clinical trials

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Principal investigator · Active not recruiting · Phase 3
NRG Oncology
2022–2031
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Principal investigator · Completed · Phase 2
Fabio Iwamoto, MD
2018–2025
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Site PI · Recruiting · Phase 3
Nuvation Bio Inc.
2023–2030
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Site PI · Available
Northwest Biotherapeutics